Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience

Files in this item

This item appears in the following Collection(s)

© The Author(s) 2018 Except where otherwise noted, this item's license is described as © The Author(s) 2018
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement